The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies

J. Beaudet; I. K. Mcniece; R. B. Jones; S. I. Bearman; P. J. Cagnoni; Y. Nieto; P. Mcsweeney; E. J. Shpall

The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies

J. Beaudet, I. K. Mcniece, R. B. Jones, S. I. Bearman, P. J. Cagnoni, Y. Nieto, P. Mcsweeney, E. J. Shpall

Stem Cell Transplantation

Research output: Contribution to journal › Review article › peer-review

Abstract

High-dose chemotherapy supported by autologous stem-cell transplantation has been widely evaluated as a strategy for high-risk patients with breast cancer. Peripheral blood progenitor cells (PBPC) have replaced over the years as the source of autologous hematopoietic graft. Hematopoietic growth factors have been studied extensively in this setting to optimize stem-cell mobilization techniques and allow a more rapid engraftment after transplantation. This article therefore provides the rationale and clinical uses of the different growth factors, such as granulocyte colony-stimulating factor (GM-CSF), Granulocyte-macrophage colony-stimulating, stem-cell factor, thrombopoietin, and rhIL-11, to support breast cancer patients undergoing dose intensive therapies. New strategies like ex-vivo expansion are also discussed. Copyright (C) 2000 by W.B. Saunders Company.

Original language	English (US)
Pages (from-to)	144-152
Number of pages	9
Journal	Seminars in Breast Disease
Volume	3
Issue number	3
State	Published - 2000

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Cite this

@article{91e76eeb407f423ab24fbb51a0cb0c81,

title = "The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies",

abstract = "High-dose chemotherapy supported by autologous stem-cell transplantation has been widely evaluated as a strategy for high-risk patients with breast cancer. Peripheral blood progenitor cells (PBPC) have replaced over the years as the source of autologous hematopoietic graft. Hematopoietic growth factors have been studied extensively in this setting to optimize stem-cell mobilization techniques and allow a more rapid engraftment after transplantation. This article therefore provides the rationale and clinical uses of the different growth factors, such as granulocyte colony-stimulating factor (GM-CSF), Granulocyte-macrophage colony-stimulating, stem-cell factor, thrombopoietin, and rhIL-11, to support breast cancer patients undergoing dose intensive therapies. New strategies like ex-vivo expansion are also discussed. Copyright (C) 2000 by W.B. Saunders Company.",

author = "J. Beaudet and Mcniece, {I. K.} and Jones, {R. B.} and Bearman, {S. I.} and Cagnoni, {P. J.} and Y. Nieto and P. Mcsweeney and Shpall, {E. J.}",

year = "2000",

language = "English (US)",

volume = "3",

pages = "144--152",

journal = "Seminars in Breast Disease",

issn = "1092-4450",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies

AU - Beaudet, J.

AU - Mcniece, I. K.

AU - Jones, R. B.

AU - Bearman, S. I.

AU - Cagnoni, P. J.

AU - Nieto, Y.

AU - Mcsweeney, P.

AU - Shpall, E. J.

PY - 2000

Y1 - 2000

N2 - High-dose chemotherapy supported by autologous stem-cell transplantation has been widely evaluated as a strategy for high-risk patients with breast cancer. Peripheral blood progenitor cells (PBPC) have replaced over the years as the source of autologous hematopoietic graft. Hematopoietic growth factors have been studied extensively in this setting to optimize stem-cell mobilization techniques and allow a more rapid engraftment after transplantation. This article therefore provides the rationale and clinical uses of the different growth factors, such as granulocyte colony-stimulating factor (GM-CSF), Granulocyte-macrophage colony-stimulating, stem-cell factor, thrombopoietin, and rhIL-11, to support breast cancer patients undergoing dose intensive therapies. New strategies like ex-vivo expansion are also discussed. Copyright (C) 2000 by W.B. Saunders Company.

AB - High-dose chemotherapy supported by autologous stem-cell transplantation has been widely evaluated as a strategy for high-risk patients with breast cancer. Peripheral blood progenitor cells (PBPC) have replaced over the years as the source of autologous hematopoietic graft. Hematopoietic growth factors have been studied extensively in this setting to optimize stem-cell mobilization techniques and allow a more rapid engraftment after transplantation. This article therefore provides the rationale and clinical uses of the different growth factors, such as granulocyte colony-stimulating factor (GM-CSF), Granulocyte-macrophage colony-stimulating, stem-cell factor, thrombopoietin, and rhIL-11, to support breast cancer patients undergoing dose intensive therapies. New strategies like ex-vivo expansion are also discussed. Copyright (C) 2000 by W.B. Saunders Company.

UR - http://www.scopus.com/inward/record.url?scp=0033797024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033797024&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0033797024

SN - 1092-4450

VL - 3

SP - 144

EP - 152

JO - Seminars in Breast Disease

JF - Seminars in Breast Disease

IS - 3

ER -

The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this